Cases
Immunomedics, Inc. (IMMU)
Securities Class Action
Overview
Overview
- Date:
- 12/21/2018
- Company Name:
- Immunomedics, Inc.
- Stock Symbol:
- IMMU
- Status:
- Closed/Complete
NEW YORK, December 21, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against Immunomedics, Inc. (NASDAQ: IMMU). Our investigation concerns whether Immunomedics has violated the federal securities laws and/or engaged in other unlawful business practices.
On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” The article reported, in part, that “[t]he FDA cited Immunomedics for a host of violations—including its handling of a data integrity breach—observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.” The article further stated that the data breach included “manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.”
On this news, Immunomedics’ share price fell by more than 20%, closing at $14.17 per share on December 20, 2018.
If you purchased or otherwise acquired Immunomedics shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” The article reported, in part, that “[t]he FDA cited Immunomedics for a host of violations—including its handling of a data integrity breach—observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.” The article further stated that the data breach included “manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.”
On this news, Immunomedics’ share price fell by more than 20%, closing at $14.17 per share on December 20, 2018.
If you purchased or otherwise acquired Immunomedics shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.